Plasma lipid profile in pregnant women with HIV receiving nevirapine

AIDS Patient Care and STDs

Volumn 23, Issue 3, 2009, Pages 147-152

  Floridia, Marco ^a   Tamburrini, Enrica ^b   Anzidei, Gianfranco ^c   Tibaldi, Cecilia ^d   Guaraldi, Giovanni ^e   Guerra, Brunella ^f   Meloni, Alessandra ^g   Vimercati, Antonella ^h   Molinari, Atim ⁱ   Pinnetti, Carmela ^b   Dalzero, Serena ^j   Ravizza, Marina ^j  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF CAGLIARI   (Italy)

^h UNIVERSITY OF BARI   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CD4+ T LYMPHOCYTE; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DATA ANALYSIS; DRUG UTILIZATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; OBSERVATIONAL STUDY; PREGNANT WOMAN; SECOND TRIMESTER PREGNANCY; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHOLESTEROL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERLIPIDEMIAS; LIPIDS; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 62949228338     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0148     Document Type: Article

References (24)

1. Anastos K, Lu D, Shi Q, et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007;45:34-42.
2. Morse CG, Kovacs JA. Metabolic and skeletal complications of HIV infection: the price of success. JAMA 2006;296:844-854.
3. Bernal E, Masiá M, Padilla S, Gutiérrez F. High-density lipoprotein cholesterol in HIV-infected patients: Evidence for an association with HIV-1 viral load, antiretroviral therapy status, and regimen composition. AIDS Patient Care STDs 2008;22:569-575.
4. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
5. Sterne JA, May M, Bucher HC, et al. HAART and the heart: Changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med 2007;261:255-267.
6. Moyle G. Metabolic issues associated with protease inhibitors. J Acquir Immune Defic Syndr 2007;45(Suppl 1):S19-26.
7. DAD Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
8. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006;8:191-203.
9. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: A randomized controlled study. J Clin Endocrinol Metab 2003;88:5186-5192.
10. Hiransuthikul N, Hiransuthikul P, Kanasook Y. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Southeast Asian J Trop Med Public Health 2007;38:69-77.
11. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-999.
12. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
13. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004;1:e19.
14. Pereira SA, Branco T, Corte-Real RM, et al. Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients. Br J Clin Pharmacol 2006;61:601-604.
15. Bergersen BM. Cardiovascular risk in patients with HIV Infection: Impact of antiretroviral therapy. Drugs 2006;66:1971-1987.
16. Floridia M, Tamburrini E, Ravizza M, et al. Lipid profile during pregnancy in HIV-infected women. HIV Clin Trials 2006;7:184-193.
17. Livingston EG, Cohn SE, Yang Y, et al. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol 2007;110:391-397.
18. El-Beitune P, Duarte G, dos Santos JE. Effect of antiretroviral agents on triglyceride levels in HIV-1-infected pregnant women. Lipids 2006;41:405-406.
19. Sankatsing RR, Wit FW, Pakker N, et al. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: The stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis 2007;196:15-22.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
21. Petit JM, Duong M, Masson D, et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004;34:569-575.
22. Prospective Studies Collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-1839.
23. Krumholz HM, Lee TH. Redefining quality - Implication of recent clinical trials. N Engl J Med 2008; 358:2537-2539.
24. Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. November 2, 2007. http://aidsinfo.nih.gov/Guidelines/ Default.aspx?MenuItem=Guidelines. (Last accessed July 7, 2008.)